We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

Fund managers haven’t disclosed any holdings of AIM yet.

AIM Hedge Fund Activity: Q1 2026 in Review

18 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q1 2026, worth a combined $103K — down 14% from $120K a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new AIM positions and 2 closed out — a net gain of 6 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $51.6K. The largest seller was DRW Securities, exiting entirely with an estimated $78.6K sold.

  • 18 institutional investors held AIM ImmunoTech (AIM) as of Q1 2026, up from 13 in Q4 2025.
  • Funds reported $103K of AIM ImmunoTech stock for Q1 2026, down 14% quarter-over-quarter.
  • 8 funds opened new AIM ImmunoTech positions in Q1 2026 and 2 closed out, a net change of +6 holders.
  • The largest AIM ImmunoTech buyer in Q1 2026 was Virtu Financial, an estimated $51.6K added.
  • The largest AIM ImmunoTech seller in Q1 2026 was DRW Securities, an estimated $78.6K sold.

Based on aggregated 13F filings for Q1 2026.